Skip to main content

Gyre Therapeutics, Inc. (GYRE) Stock Forecast

Data as of May 2, 2026

Healthcare · Current price $7.83 (+1.95%)

Consensus Target
$16.00
Upside
+117.1%
Analysts
Rating

Price Target Range

Low $16.00High $16.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

No ratings in the last 3 months.
Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0

6-Month Trend

No rating trend data.

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Oct 10, 2025Roger SongJefferies$16.00+104.3%

GYRE vs Sector & Market

MetricGYREHealthcare AvgLarge Cap Avg
Analyst Rating2.242.41
Analyst Count818
Target Upside+117.1%+1150.1%+14.9%
P/E Ratio348.006.5431.19

Revenue Estimates

PeriodLowAvgHigh#
2026-06-30$23M$33M$43M2
2026-09-30$25M$35M$48M1
2026-12-31$27M$37M$51M1
2027-12-31$115M$133M$157M1
2028-12-31$380M$437M$518M1
2029-12-31$231M$266M$315M1
2030-12-31$269M$310M$368M1

EPS Estimates

PeriodLowAvgHigh#
2026-06-30$-0.08$-0.05$-0.032
2026-09-30$-0.12$-0.08$-0.051
2026-12-31$-0.14$-0.10$-0.061
2027-12-31$-0.24$-0.20$-0.161
2028-12-31$1.42$1.71$2.121
2029-12-31$0.09$0.11$0.141
2030-12-31$0.21$0.25$0.311

Frequently Asked Questions

What is the analyst consensus for GYRE?

The consensus among 0 analysts covering Gyre Therapeutics, Inc. (GYRE) is — with an average price target of $16.00.

What is the highest price target for GYRE?

The highest price target for GYRE is $16.00, set by Roger Song at Jefferies on 2025-10-10.

What is the lowest price target for GYRE?

The lowest price target for GYRE is $16.00, set by Roger Song at Jefferies on 2025-10-10.

How many analysts cover GYRE?

0 analysts have issued ratings for Gyre Therapeutics, Inc. in the past 12 months.

Is GYRE a buy or sell right now?

Based on 0 analyst ratings, GYRE has a consensus rating of — with a +117.1% upside to the consensus target of $16.00.

What are the earnings estimates for GYRE?

Analysts estimate GYRE will report EPS of $-0.05 for the period ending 2026-06-30, with revenue estimated at $33M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.